Circulating HPV DNA in patients with cervical precancerous lesions and cervical cancer

Česká verzia

Authors: Š. Krivuš; E. Kúdela; S. Meršáková; V. Holubeková; Z. Laučeková; E. Gabonová; M. Ňachajová; P. Žúbor; K. Biringer
Authors place of work: Gynekologicko-pôrodnícka klinika JLF UK, Martin, Slovenská republika, prednosta prof. MUDr. P. Žúbor, PhD, DrSc., MBA, FRSM
Published in the journal: Ceska Gynekol 2020; 85(3): 214-219
Category:

Summary

Objective: In our review article we focused on the circulating HPV DNA and its potential role in the pathogenesis of cervical cancer and in the evaluation of patients´ prognosis with cervical cancer

Design: The article is a systematic review study analyzing available scientific articles focused on the circulating HPV DNA.

Setting: Clinic of Obstetrics and Gynecology, Jesenius faculty of Medicine in Martin, Comenius University in Bratislava, Slovakia.

Methods: In our study we searched the medical database PubMed with the key words: circulating HPV DNA, cervical cancer, cervical precanceroses. The core of our work is focused on the scientific articles published in English language since year 1995.

Results: We identified 13 studies in PubMed database analyzing the circulating HPV DNA in the process of cervical carcinogenesis. It is clear from the results that circulating HPV DNA is a significant prognostic marker of cervical malignant diseases including the early stages.

Conclusion: The results focused on circulating HPV DNA show the significance of molecular biology in assessing the prognosis of cervical cancer. This idea has to be supported by further relevant studies. The uniformity of studies and use of the most sophisticated methods could help to answer the question about the real role of circulating HPV DNA in the process of cervical carcinogenesis and disease progression.

Keywords:

cervical cancer – HPV – circulating HPV DNA

Zdroje

1. Bodaghi, S., Wood, LV., Roby, G., et al. Could human papillomaviruses be spread through blood? J Clin Microbiol, 2005, 43(11), p. 5428–5434.

2. Bouvard, R., Baan, K., Straif, Y., Grosse, B., et al. A review of human carcinogens-part B: biological agents. Lancet Oncol, 2009, 10(4), p. 321–322.

3. Capone, RB., Pai, SI., Koch, WM., et al. Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. Clin Cancer Res, 2000, 6, p. 4171–4175.

4. Chen, ACH., Keleher, A., Kedda, MA., et al. Human papillomavirus DNA detected in peripheral blood samples from healthy Australian male blood donors. J Medic Virol, 2009, 81, p. 1792– 1796.

5. Cocuzza, CE., Martinelli, M., Sina, F., et al. Human papillomavirus DNA detection in plasma and cervical samples of women with recent history of low-grade or precancerous cervical dysplasia. PLoS One, 2017, 12(11), p. e0188592.

6. Dong, SM., Pai, SI., Rha, SH., et al. Detection and quantitation of human papillomavirus DNA in the plasma of patients with cervical carcinoma. Cancer Epidemiol Biomarkers Prev, 2002, 11(1), p. 3–6.

7. Ferlay, J., Soerjomataram, I., Ervik, M., et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available online: http://globocan. iarc.fr.

8. Gnanamony, M., Peedicayil, A., Subhashini, J., et al. Detection and quantitation of HPV 16 and 18 in plasma of Indian women with cervical cancer. Gynecol Oncol, 2010, 116, 447–451.

9. Han, K. Circulating human papillomavirus DNA as a biomarker of response in patients with locally advanced cervical cancer treated with definitive chemoradiation. JCO Precision Oncology, 2, 2018, doi:10.1200/PO.18.00152.

10. Herfs, M., Yomamoto, Y., Laury, A., et al. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci, 2012, 109, p. 10516–10521.

11. Ho, CM., Yang, SS., Chien, TY., et al. Detection and quantitation of human papillomavirus type 16, 18 and 52 DNA in the peripheral blood of cervical cancer patients. Gynecol Oncol, 2005, 99(3), p. 615–621.

12. Jeannot, E., Becette, V., Campitelli, M., et al. Circulating human papillomavirus DNA detected using droplet digital PCR in the serum of patients diagnosed with early stage human papillomavirus-associated invasive carcinoma. J Pathol Clin Res, 2016, 2(4), p. 201–209.

13. Kang, Z. Circulating cell-free DNA for metastatic cervical cancer detection, genotyping, and monitoring. Clin Cancer Res, 23, 2017, p. 6856–6862.

14. Kay, P., Allan, B., Denny, L., et al. Detection of HPV 16 and HPV 18 DNA in the blood of patients with cervical cancer. J Med Virol, 2005, 75(3), p. 435–439.

15. Lee, TH., Montalvo, L., Chrebtow, V., Busch, MP. Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion, 2001, 41, p. 276–228.

16. Pao, CC., Hor, JJ., Yang, FP., et al. Detection of human papillomavirus mRNA and cervical cancer cells in peripheral blood of cervical cancer patients with metastasis. J Clin Oncol, 1997, 15, p. 1008–1012.

17. Pornthanakasem, W., Shotelersuk, K., Termrungruanglert, W.,et al. Human papillomavirus DNA in plasma of patients with cervical cancer. BMC Cancer, 2001, 1, p. 2.

18. Roperto, S., Comazzi, S., Ciusani, E., et al. PBMCs are additional sites of productive infection of bovine papillomavirus type 2. J Gen Virol, 2011, 92(Pt 8), p. 1787–1794.

19. Sathish, N., Abraham, P., Peedicayil, A., et al. HPV DNA in plasma of patients with cervical carcinoma. J Clin Virol, 2004, 31(3), p. 204–209.

20. Singh, B., Fleury, C., Jalalvand, F., Riesbeck, K. Human pathogens utilize host extracellular matrix proteins laminin and collagen for adhesion and invasion of the host. FEMS Microbiol Rev, 2012, 36(6), p. 1122–1180.

21. Smith, JL., Lidke, DS., Ozbun, MA. Virus activated filopodia promote human papillomavirus type 31 uptake from the extracellular matrix. Virology, 2008, 381(1), p. 16–21.

22. Stocco dos Santos. RC., Lindsey, CJ., Ferraz, OP., et al. Bovine papillomavirus transmission and chromosomal aberrations: an experimental model. J Gen Virol, 1998, 79, p. 2127–2135.

23. Stroun, M., Maurice, P., Vasioukhin, V., et al. The origin and mechanism of circulating DNA. Ann NY Acad Sci, 2000, 906, p. 161–168.

24. Tseng, CJ., Pao, CC., Lin, JD., et al. Detection of human papillomavirus types 16 and 18 mRNA in peripheral blood of advanced cervical cancer patients and its association with prognosis. J Clin Oncol, 1999, 17, p. 1391–1396.

25. Walboomers, JM., Jacobs, MV., Manos, MM., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 1991, 189(1), p. 12–19.

26. Wei, YC., Chou, YS., Chu, TY. Detection and typing of minimal human papillomavirus DNA in plasma. Int J Gynaecol Obstet, 2007, 96(2), p. 112–116.

27. Widschwendter, A., Blassnig, A., Wiedemair, A., et al. Human papillomavirus DNA in sera of cervical cancer patients as tumor marker. Cancer Lett, 2003, 202, p. 231–239.

28. Yang, EJ., Quick, MC., Hanamornroongruang, S., et al. Microanatomy of the cervical and anorectal squamocolumnar junctions: a proposed model for anatomical differences in HPVrelated cancer risk. Mod Pathol, 2015, 28(7), p. 994–1000.